Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.50 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.47 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | GABRP | O00591 | 2/20 | 0.41 |
| ▸ | GABRD | O14764 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9504528 | 0.98 | HCAR2 (0.48) | HCAR2P4HA1P4HTMMIFKDM4E | |
| SCHEMBL6628143 | 0.83 | SMN1; SMN2 (0.40) | P4HA1P4HTMMIFKDM4EHCAR3 | |
| SCHEMBL30668508 | 0.81 | HCAR2 (0.48) | HCAR2P4HA1P4HTMMIFKDM4E | |
| SCHEMBL4121189 | 0.81 | HCAR2 (0.48) | HCAR2P4HA1P4HTMMIFKDM4E | |
| SCHEMBL13069420 | 0.81 | CYP2A6 (0.34) | HCAR2P4HA1P4HTMMIFKDM4E | |
| SCHEMBL31681508 | 0.81 | HCAR2 (0.48) | HCAR2P4HA1P4HTMMIFKDM4E | |
| SCHEMBL15350036 | 0.81 | HCAR2 (0.48) | HCAR2P4HA1P4HTMMIFKDM4E | |
| SCHEMBL6052889 | 0.81 | HCAR2 (0.48) | HCAR2P4HA1P4HTMMIFKDM4E | |
| SCHEMBL2601852 | 0.81 | HCAR2 (0.48) | HCAR2P4HA1P4HTMMIFKDM4E | |
| SCHEMBL3998717 | 0.81 | NNMT (0.47) | TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0325061-B1 | Process for producing poly (para-phenylene-sulfide) | TOSOH CORP (JP) | 1995-12-06 | — | — | EP | claimed |
| EP-0272903-B1 | PROCESS FOR PRODUCING A POLYARYLENE SULFIDE | Tosoh Corporation (JP) | 1993-07-21 | — | — | EP | claimed |
| US-20250213540-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCING LOW IMPURITY CONCENTRATIONS OF THE SAME | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-07-03 | — | — | US | disclosed |
| EP-3632910-B1 | 3,4-DIHYDROQUINOLINONES AS FXR RECEPTOR AGONISTS | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-11339147-B2 | Lactam compound as FXR receptor agonist | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2022-05-24 | — | — | US | disclosed |
| WO-2020244970-A1 | NEW CARBOCYCLIC PYRIDINE CARBOXAMIDES | BASF SE (DE) | 2020-12-10 | — | — | WO | disclosed |
| US-20200247798-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA KIRIN CO LTD (JP) | 2020-08-06 | — | — | US | disclosed |
| US-20200190074-A1 | LACTAM COMPOUND AS FXR RECEPTOR AGONIST | MEDSHINE DISCOVERY INC. (CN) | 2020-06-18 | — | — | US | disclosed |
| EP-3632910-A1 | LACTAM COMPOUND AS FXR RECEPTOR AGONIST | Medshine Discovery Inc. (CN) | 2020-04-08 | — | — | EP | disclosed |
| EP-3252046-B1 | FUSED HETEROCYCLIC COMPOUND HAVING CYCLOALKYLPYRIDYL GROUP OR SALT THEREOF, AND AGRICULTURAL OR HORTICULTURAL INSECTICIDE CONTAINING SAID COMPOUND AND USE METHOD THEREFOR | NIHON NOHYAKU CO LTD (JP) | 2020-04-01 | — | — | EP | disclosed |
| CN-107001342-B | Novel compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-02-07 | — | — | CN | disclosed |
| WO-2009112565-A1 | THIAZOLYL-DIHYDRO-INDAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-17 | — | — | WO | disclosed |
| US-7557213-B2 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7361679-B2 | 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2008-04-22 | — | — | US | disclosed |
| US-20070167443-A1 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-20070167443-A1 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| WO-2007059108-A2 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| EP-0325061-B1 | Process for producing poly (para-phenylene-sulfide) | TOSOH CORP (JP) | 1995-12-06 | — | — | EP | disclosed |
| US-5037953-A | Dehydrating mixture of alkali metal sulfide, polar aprotic solvent, sodium salt of aromatic acid, reacting with p-dihalobenzene | TOSOH CORPORATION (JP) | 1991-08-06 | — | — | US | disclosed |
| EP-0325061-A2 | Process for producing poly (para-phenylene-sulfide) | Tosoh Corporation (JP) | 1989-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339147-B2 | Lactam compound as FXR receptor agonist | NR1H4, GPBAR1, SLC10A1 | HCAR2 169/4885P4HA1 4034/4885P4HTM 3306/4885 |
| US-20200190074-A1 | LACTAM COMPOUND AS FXR RECEPTOR AGONIST | NR1H4, GPBAR1, SLC10A1 | HCAR2 169/4885P4HA1 4034/4885P4HTM 3306/4885 |
| US-20070167443-A1 | Substituted quinolones and methods of use | TOP2A, NQO2, TOP2B | HCAR2 3104/4885P4HA1 1271/4885P4HTM 1526/4885 |
| US-20250213540-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCING LOW IMPURITY CONCENTRATIONS OF THE SAME | MCCC2, CHRM2, CHRM5 | HCAR2 1362/4885P4HA1 1324/4885P4HTM 2316/4885 |
| US-20200247798-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | TAAR1, SLC6A1, GABBR1 | HCAR2 716/4885P4HA1 185/4885P4HTM 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.